NUVALENT INC-A (NUVL) Stock Price, Forecast & Analysis
USA - NASDAQ:NUVL - US6707031075 - Common Stock
NUVL Key Statistics, Chart & Performance
The current stock price of NUVL is 92.7 USD. In the past month the price increased by 8.52%. In the past year, price decreased by -3.49%.
NUVL Latest News, Press Relases and Analysis
NUVL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.21 | 387.53B | ||
| AMGN | AMGEN INC | 14.49 | 170.55B | ||
| GILD | GILEAD SCIENCES INC | 15.1 | 153.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24 | 106.82B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.71 | 57.20B | ||
| ARGX | ARGENX SE - ADR | 63.16 | 52.14B | ||
| INSM | INSMED INC | N/A | 39.20B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.36 | 36.42B | ||
| NTRA | NATERA INC | N/A | 27.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.66B | ||
| BIIB | BIOGEN INC | 9.24 | 22.69B |
Related stock screener links
About NUVL
Company Profile
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 200 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. The company is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Company Info
NUVALENT INC-A
One Broadway, 14Th Floor
Cambridge MASSACHUSETTS US
CEO: James R. Porter
Employees: 200
Phone: 18573577000
NUVALENT INC-A / NUVL FAQ
What does NUVALENT INC-A do?
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 200 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. The company is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
What is the stock price of NUVALENT INC-A today?
The current stock price of NUVL is 92.7 USD. The price increased by 0.66% in the last trading session.
Does NUVL stock pay dividends?
NUVL does not pay a dividend.
How is the ChartMill rating for NUVALENT INC-A?
NUVL has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of NUVALENT INC-A (NUVL)?
NUVALENT INC-A (NUVL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.9).
Should I buy NUVL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NUVL.
What is the Short Interest ratio of NUVALENT INC-A (NUVL) stock?
The outstanding short interest for NUVALENT INC-A (NUVL) is 7.6% of its float.
NUVL Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NUVL. When comparing the yearly performance of all stocks, NUVL is one of the better performing stocks in the market, outperforming 72.54% of all stocks.
NUVL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NUVL. No worries on liquidiy or solvency for NUVL as it has an excellent financial health rating, but there are worries on the profitability.
NUVL Financial Highlights
Over the last trailing twelve months NUVL reported a non-GAAP Earnings per Share(EPS) of -4.9. The EPS decreased by -76.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33% | ||
| ROE | -36.54% | ||
| Debt/Equity | 0 |
NUVL Forecast & Estimates
20 analysts have analysed NUVL and the average price target is 121.85 USD. This implies a price increase of 31.45% is expected in the next year compared to the current price of 92.7.